Use of ADHD drugs in the Nordic countries: A population-based comparison study

Acta Psychiatrica Scandinavica

Volumn 123, Issue 5, 2011, Pages 360-367

  Zoega H ^a   Furu, K ^b,c   Halldorsson M ^d   Thomsen, P H ^e   Sourander, A ^f   Martikainen, J E ^g  

^a UNIVERSITY OF ICELAND   (Iceland)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d Icelandic Directorate of Health   (Iceland)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g SOCIAL INSURANCE INSTITUTION   (Finland)

Author keywords

Attention deficit hyperactivity disorder; Central nervous system stimulants; Drug utilisation; Pharmacoepidemiology; Prevalence

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; DEXMETHYLPHENIDATE; FENCAMFAMIN; FENETYLLINE; FENOZOLONE; METHAMPHETAMINE; MODAFINIL; PEMOLINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FINLAND; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HUMAN; ICELAND; INFANT; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRESCHOOL CHILD; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; SCHOOL CHILD; SEX DIFFERENCE; SEX RATIO; SWEDEN;

ADOLESCENT; ADULT; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; FINLAND; HUMANS; ICELAND; MALE; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; SCANDINAVIA; SEX FACTORS; SYMPATHOMIMETICS;

EID: 79954529331     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01607.x     Document Type: Article

References (51)

1. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord 2007;10:335-342.
2. Mccarthy S, Asherson P, Coghill D et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009;194:273-277.
3. Zoega H, Baldursson G, Halldorsson M. [Use of methylphenidate among children in Iceland 1989-2006]. Laeknabladid 2007;93:825-832 [Icelandic].
4. Asheim H, Nilsen KB, Johansen K, Furu K. [Prescribing of stimulants for ADHD in Nordland County]. Tidsskr Nor Laegeforen 2007;127:2360-2362 [Norwegian].
5. Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff (Millwood) 2007;26:450-457.
6. Winterstein AG, Gerhard T, Shuster J et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008;42:24-31.
7. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006;163:579-585.
8. Asherson P, Chen W, Craddock B, Taylor E. Adult attention-deficit hyperactivity disorder: recognition and treatment in general adult psychiatry. Br J Psychiatry 2007;190:4-5.
9. Okie S. ADHD in adults. N Engl J Med 2006;354:2637-2641.
10. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003;2:104-113.
11. Polanczyk G, De Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-948.
12. Fayyad J, De Graaf R, Kessler R et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-409.
13. Kessler RC, Adler L, Barkley R et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-723.
14. Steinhausen HC. The heterogeneity of causes and courses of attention-deficit/hyperactivity disorder. Acta Psychiatr Scand 2009;120:392-399.
15. Hechtman L, Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr Drugs 2003;5:787-794.
16. Molina BS, Hinshaw SP, Swanson JM et al. The MTA at 8years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009;48:484-500.
17. Asherson P, Adamou M, Bolea B et al. Is ADHD a valid diagnosis in adults? Yes. BMJ 2010;340:c549.
18. Moncrieff J, Timimi S. Is ADHD a valid diagnosis in adults? No. BMJ 2010;340:c547.
19. Steinhausen HC. Attention-deficit hyperactivity disorder in a life perspective. Acta Psychiatr Scand 2003;107:321-322.
20. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94.
21. World Health Organization WHO collaborating centre for drug statistics methodology: ATC/DDD index. Oslo: World Health Organization, 2008. Available at: (accessed August 2008-November 2009).
22. Iceland Medicines Control Agency: summary of product characteristics (SPC). Available at:)/ (accessed July 2008-November 2009).
23. Danish Medicines Agency: summaries of product characteristics (SPC). Available at: 2005 (accessed August 2008-November 2009).
24. Finland National Agency for Medicines: summaries of product characteristics (SPC). Available at: (accessed August 2008).
25. Sweden Medicinal Products Agency: Läkemedelsfakta. Available at: (accessed August 2008-November 2009).
26. Norwegian Medicines Agency: summary of product characteristics. Available at: (accessed August 2008-November 2009).
27. Norwegian Directorate of Health and Social Services. [Guidelines for diagnostic and treatment of attention deficit hyperactivity disorder in children, adolescents and adults in Norway]. Veileder for diagnostisering og behandling av AD/HD. Oslo: Norwegian Directorate of Health and Social Services, 2007 [Norwegian].
28. Iceland Social Insurance. [Cost of CNS drugs for ADHD] Kostna{eth}ur TR 2007: Örvandi lyf, lyf notu{eth} vi{eth} ADHD og lyf sem efla heilastarfsemi. Reykjavik: Iceland Social Insurance, 2008. Available at: [Icelandic].
29. Finnish Medical Society Duodecim/Current Care. The Finnish Current Care Guidelines: treatment for attention-deficit hyperactivity disorder (ADHD) in children and adolescents. Helsinki: Finnish Medical Society Duodecim/Current Care, 2008. Available at:
30. Swedish Medicinal Product Agency. Available at: (accessed August-December 2009).
31. Directorate of Health in Iceland. [Clinical Guidelines for diagnosing and treating ADHD]. Vinnulag vi{eth} greiningu og me{eth}fer{eth} athyglisbrests me{eth} ofvirkni (ADHD). Seltjarnarnes: Directorate of Health in Iceland, 2007. Available at: [Icelandic].
32. Costello EJ, Mustillo S, Erkanli A, Keeler G, Angold A. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 2003;60:837-844.
33. Ford T, Goodman R, Meltzer H. The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry 2003;42:1203-1211.
34. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005;57:1215-1220.
35. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006;36:159-165.
36. Nutt DJ, Fone K, Asherson P et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007;21:10-41.
37. Zito JM, Safer DJ, Berg LT et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008;2:26.
38. Faber A, De Jong-Van Den Berg LT, Van Den Berg PB, Tobi H. Psychotropic co-medication among stimulant-treated children in The Netherlands. J Child Adolesc Psychopharmacol 2005;15:38-43.
39. Jick H, Kaye JA, Black C. Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK. Br J Gen Pract 2004;54:345-347.
40. Lundström B, Voutilainen A, Sourander A. [Use of Psychostimulants in Finland]. Suom Lääkäril 2006;49:5184-5189 [Finnish].
41. Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U, Halldorsson M. Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 2009;19:757-764.
42. Hsia Y, Maclennan K. Rise in psychotropic drug prescribing in children and adolescents during 1992-2001: a population-based study in the UK. Eur J Epidemiol 2009;24:211-216.
43. Lee SI, Schachar RJ, Chen SX et al. Predictive validity of DSM-IV and ICD-10 criteria for ADHD and hyperkinetic disorder. J Child Psychol Psychiatry 2008;49:70-78.
44. Sweden Medicinal Products Agency:Läkemedelsbehandling av ADHD- Ny rekommendation. Available at: [Swedish].
45. The Danish National Board of Health. [Clinical Guidelines, Treatment with Psychotropic Drugs] Vejledning om behandling med antidepressiva. Vejledning om behandling med antipsykotika. Vejledning om behandling af børn med antidepressiva, antipsykotika og centralstimulerende midler. Copenhagen: The Danish National Board of Health, 2000 [Danish].
46. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 1995;142:1103-1112.
47. Finland National Agency for Medicines: drug consumption in 2005-2008. Available at: (accessed November 2009).
48. Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 2008;152:394-399.
49. Greenhill LL, Biederman J, Boellner SW et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:503-511.
50. Gould MS, Walsh BT, Munfakh JL et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009;166:992-1001.
51. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006;354:1445-1448.